Araştırma Makalesi

Cytotoxic activity of TRPV4 antagonist RN-1734 in G-361 human melanoma cancer cell line

Cilt: 48 Sayı: 3 30 Eylül 2023
PDF İndir
EN TR

Cytotoxic activity of TRPV4 antagonist RN-1734 in G-361 human melanoma cancer cell line

Öz

Purpose: Intracellular calcium (Ca2+) signaling plays a role in many cellular events, such as cell proliferation and differentiation, gene transcription, oxidative stress, the antioxidant system, and apoptosis. Transient receptor potential vanilloid 4 (TRPV4) channels are non-selective cation (Ca2+) channels. The present study aims to investigate the cytotoxic activity of RN-1734, a transient receptor potential vanilloid 4 (TRPV4) antagonist, in the G361 human melanoma cancer cell line. Materials and Methods: The effects of RN-1734 on G361 cell viability at concentrations of 1, 5, 25, 50, and 100 μM were measured using the 3-(4,5-dimethylthiazol-2-il)-2,5-diphenyltetrazolium bromide (MTT) method. Total antioxidant status (TAS) and total oxidant status (TOS) levels were determined using a ready-made commercial kit, after which oxidative stress index (OSI) values were calculated. To determine the apoptotic effects of RN-1734, Bcl-2, Bax, and p53 expression levels, caspase-3 and -8 activities were examined via quantitative real-time PCR analysis. Results: G361 cell viability significantly decreased to 82.72, 72.81, 56.36, 39.16 and 18.96% in RN-1734 groups (1, 5, 25, 50 and 100 μM) compared to the control group (100.00%). At IC50 concentration (39.48 μM), RN-1734 application (3.35 mmol/g prot.-TAS, 45.87 μmol/g prot.-TOS, and 1501.97 AU-OSI) increased the TAS level (2.17 mmol/g prot.) and decreased the TOS level (55.41 μmol/g prot.) and OSI value (3142.76 AU) compared to the control group. Conclusion: Our findings show that RN-1734 may be a novel therapeutic approach to treating melanoma by decreasing the cell viability of G361 human melanoma cancer cells.

Anahtar Kelimeler

Cell viability, G361 human melanoma cancer cells, oxidative stress, RN-1734, TRPV4

Teşekkür

We appreciate Prof. Sefa Çelik for supplying the lab equipment.

Kaynakça

  1. Kim GH, Fang XQ, Lim WJ, Park J, Kang TB, Kim JH et al. Cinobufagin suppresses melanoma cell growth by inhibiting LEF1. Int J Mol Sci. 2020;21:6706.
  2. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T et al. Cancer treatment and survivorship statistics. CA Cancer J Clin. 2012;62:220-41.
  3. Park KH, Choi JH, Song YS, Kim GC, Hong JW. Ethanol extract of asiasari radix preferentially induces apoptosis in G361 human melanoma cells by differential regulation of p53. BMC Complement Altern Med. 2019;19:231.
  4. Leonardi GC, Falzone L, Salemi R, Zanghì A, Spandidos DA, Mccubrey JA et al. Cutaneous melanoma: From pathogenesis to therapy. Int J Oncol. 2018;52:1071-80.
  5. Parkin DM, Mesher D, Sasieni P. Cancers attributable to solar (ultraviolet) radiation exposure in the UK in 2010. Br J Cancer. 2011;105:66-9.
  6. Zhang W, Xie X, Huang Z, Zhong X, Liu Y, Cheong KL et al. The integration of single-cell sequencing, TCGA, and GEO data analysis revealed that PRRT3-AS1 is a biomarker and therapeutic target of SKCM. Front Immunol. 2022;13:919145.
  7. Chen YN. Dacarbazine inhibits proliferation of melanoma FEMX-1 cells by up-regulating expression of miRNA-200. Eur Rev Med Pharmacol Sci. 2017;21:1191-7.
  8. Yanarojana M, Nararatwanchai T, Thairat S, Tancharoen S. Antiproliferative activity and induction of apoptosis in human melanoma cells by Houttuynia cordata thunb extract. Anticancer Res. 2017;37:6619-28.
  9. Stewart TA, Yapa KT, Monteith GR. Altered calcium signaling in cancer cells. Biochim Biophys Acta. 2015;1848:2502-11.
  10. Yu S, Huang S, Ding Y, Wang W, Wang A, Lu Y. Transient receptor potential ion-channel subfamily V member 4: a potential target for cancer treatment. Cell Death Dis. 2019;10:497.

Kaynak Göster

APA
Güleş, Ö., Bilici, E., Kurbasevıc, E., Lenger, Ö. F., Boyacıoğlu, M., & Epikmen, E. T. (2023). Cytotoxic activity of TRPV4 antagonist RN-1734 in G-361 human melanoma cancer cell line. Cukurova Medical Journal, 48(3), 939-947. https://doi.org/10.17826/cumj.1324675
AMA
1.Güleş Ö, Bilici E, Kurbasevıc E, Lenger ÖF, Boyacıoğlu M, Epikmen ET. Cytotoxic activity of TRPV4 antagonist RN-1734 in G-361 human melanoma cancer cell line. Cukurova Med J. 2023;48(3):939-947. doi:10.17826/cumj.1324675
Chicago
Güleş, Özay, Esra Bilici, Emira Kurbasevıc, Ömer Faruk Lenger, Murat Boyacıoğlu, ve Erkmen Tuğrul Epikmen. 2023. “Cytotoxic activity of TRPV4 antagonist RN-1734 in G-361 human melanoma cancer cell line”. Cukurova Medical Journal 48 (3): 939-47. https://doi.org/10.17826/cumj.1324675.
EndNote
Güleş Ö, Bilici E, Kurbasevıc E, Lenger ÖF, Boyacıoğlu M, Epikmen ET (01 Eylül 2023) Cytotoxic activity of TRPV4 antagonist RN-1734 in G-361 human melanoma cancer cell line. Cukurova Medical Journal 48 3 939–947.
IEEE
[1]Ö. Güleş, E. Bilici, E. Kurbasevıc, Ö. F. Lenger, M. Boyacıoğlu, ve E. T. Epikmen, “Cytotoxic activity of TRPV4 antagonist RN-1734 in G-361 human melanoma cancer cell line”, Cukurova Med J, c. 48, sy 3, ss. 939–947, Eyl. 2023, doi: 10.17826/cumj.1324675.
ISNAD
Güleş, Özay - Bilici, Esra - Kurbasevıc, Emira - Lenger, Ömer Faruk - Boyacıoğlu, Murat - Epikmen, Erkmen Tuğrul. “Cytotoxic activity of TRPV4 antagonist RN-1734 in G-361 human melanoma cancer cell line”. Cukurova Medical Journal 48/3 (01 Eylül 2023): 939-947. https://doi.org/10.17826/cumj.1324675.
JAMA
1.Güleş Ö, Bilici E, Kurbasevıc E, Lenger ÖF, Boyacıoğlu M, Epikmen ET. Cytotoxic activity of TRPV4 antagonist RN-1734 in G-361 human melanoma cancer cell line. Cukurova Med J. 2023;48:939–947.
MLA
Güleş, Özay, vd. “Cytotoxic activity of TRPV4 antagonist RN-1734 in G-361 human melanoma cancer cell line”. Cukurova Medical Journal, c. 48, sy 3, Eylül 2023, ss. 939-47, doi:10.17826/cumj.1324675.
Vancouver
1.Özay Güleş, Esra Bilici, Emira Kurbasevıc, Ömer Faruk Lenger, Murat Boyacıoğlu, Erkmen Tuğrul Epikmen. Cytotoxic activity of TRPV4 antagonist RN-1734 in G-361 human melanoma cancer cell line. Cukurova Med J. 01 Eylül 2023;48(3):939-47. doi:10.17826/cumj.1324675